• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Biomarkers market will hit $19.86 billion in 2015

Report: Biomarkers market will hit $19.86 billion in 2015

June 28, 2011
CenterWatch Staff

A new report from visiongain, a London-based business information provider, predicts the global biomarkers market will be worth $19.86 billion in 2015.

The market generated $14.18 billion in 2010, according to the just published Biomarkers: Technological and Commercial Outlook 2011-2021.

A biomarker can be defined as a factor that can be measured with precision and that reflects a normal biological process or a therapeutic response. Biomarkers have great utility in the pharmaceutical industry as they can be used to deduce the pharmacokinetic-pharmacodynamic relationships of therapies as well as help in the determination of drug efficacy. This market has significant potential for growth because the utility of biomarkers spans all therapeutic areas and their use directly affects our ability to diagnose and monitor disease progression.

"Accurate non-invasive methods for monitoring and quantifying the concentrations of biomarkers are vital for the early diagnosis of disease,” according to the report analyst. “At present, there is significant research activity in the discovery of novel biomarkers for a range of diseases. Over the course of the decade, the emphasis will gradually shift from biomarker discovery to biomarker validation. A key market driver will be patient stratification, especially for therapeutic areas such as oncology, where the disease is highly heterogeneous."

Visiongain said the world biomarkers market will benefit from the manufacture of non-invasive methods for imaging biomarkers. The fields of genomics and proteomics will lead to new insights about disease mechanisms and facilitate the discovery of biomarkers.

Visiongain predicted this market will grow steadily to 2021. As the field of biomarker research matures, patient stratification will become routine.

Visiongain is an independent media company, producing a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the pharmaceutical, telecom, energy, defense and materials sectors. It publishes reports produced by its in-house analysts.

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing